[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634764":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":11,"centralContacts":29,"locations":35,"responsibleParty":46,"collaborators":11,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":11,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":11,"enrollmentInfo":59,"targetDuration":11,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":70,"whyStopped":11,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Sohag University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"group 1 PRF injection","ACTIVE_COMPARATOR",null,[13],"Biological: PRF group",{"label":15,"type":10,"description":11,"interventionNames":16},"group 2 vitamin D injection",[17],"Drug: Vitamin D",[19,24],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":11},"BIOLOGICAL","PRF group","intralesional PRF injection in common warts",[9],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"DRUG","Vitamin D","intralesional vitamin D injection in common wart",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"basma alaaeldin mohamed, resident","CONTACT","01093827856","basmaelbolok2025@gmail.com",[36],{"facility":5,"status":11,"city":37,"state":11,"zip":11,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":11},"Sohag","Egypt","EG",{"type":41,"coordinates":42},"Point",[43,44],31.69478,26.55695,{"lat":44,"lon":43},{"type":47,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Bassma Alaaeldin Mohamed","Dermatology , Venerology and Andrology Resident at Sohag University Hospital","100634764","new-treatment-of-common-wart-100634764",false,"NCT07543926","New Treatment of Common Wart","Evaluation Of Intralesional Platelet-Rich Fibrin Versus Intralesional Vitamin D In Treatment Of Common Warts","Inclusion Criteria:\n\n* \\- Age more than or equal to 18 years\n* Clinically and dermoscopically confirmed Common warts of both sex\n* patient not receiving previous treatment at least one month before recruitment in our study\n* Single or multiple lesions suitable for injection.\n\nExclusion Criteria:\n\n* Chronic Systemic desise (DM , HTN , Autoimmune , immunosuppressive disorders eg , lupus , renal or hepatic failure ) or Hematologic Conditions (anemia : hemoglobin level below 10 g\u002Fdl , thrombocytopenia : platelet count below 150,000 \u002FµL ) Infectious Diseases , Local bacterial or fungal infection at the lesions .\n\nPregnancy, Lactation , patients who has hypersensitivity of vitamin D .","ALL","18 Years",{"count":60,"type":61},70,"ESTIMATED","INTERVENTIONAL",[64],"NA","this study aims to compare the efficacy and safety of platelet rich fibrin injection versus intralesional vitamin D injection in the treatmentof common warts. PRF, as an autologous biological material , may enhance tissue regeneration and immune response.",[67],"Common Warts (Verruca Vulgaris)",[69],"PRF injection","NOT_YET_RECRUITING","2026-04-18",{"date":73,"type":74},"2026-04-22","ACTUAL",{"date":76,"type":61},"2026-04-06",{"date":78,"type":61},"2026-12-30",{"name":5,"class":6},1]